FDA approves blood-based cancer test in medical breakthrough

Category: Health

Guardant Health's blood test, Shield, received FDA approval for colorectal cancer screening, potentially allowing Medicare coverage for older adults. The test, previously available as a laboratory-developed test, is more convenient than traditional feces-based tests and aims to reach over 50 million unscreened individuals. Shield detected 83% of colorectal cancers, while the stool test Cologuard had a 92.3% sensitivity rate.

Keywords: Guardant Health, colorectal cancer, FDA approval

Source: New York Post

Update At: 7/30/2024

Related Sources